Skip to main content
Log in

Evaluation of the Antiretroviral Activity of a New Polyherbal Drug (Immu-25) in Patients with HIV Infection

  • Original Research Article
  • Published:
Drugs in R & D Aims and scope Submit manuscript

Abstract

Objective: To evaluate the clinical efficacy and safety of a new polyherbal preparation, Immu-25, in HIV-infected patients.

Methods: 36 patients (10 female, 26 male) with a mean age of 35 ± 10 years, with confirmed HIV infection with a CD4 count <500 cells/μL, received two capsules of the test drug twice daily for 18 months in this open-label pilot study. Patients were evaluated at monthly intervals for general signs and symptoms, development of opportunistic infections, and changes in weight and performance index. Lymphocyte phenotyping and routine haematological, biochemical, hepatic and renal parameters were recorded after every 6 months of drug therapy. Viral load was evaluated before and after every 6 months of treatment.

Results: The polyherbal test preparation produced good symptomatic improvement within 6 months. There was an increase in mean (95% CI) weight from 58 (53–64)kg to 63 (56–69)kg, 64 (58–72)kg and 68 (62–74)kg after 6, 12 and 18 months of treatment, respectively. The incidence and severity of symptoms such as diarrhoea, fatigue, anorexia, cough and fever decreased with drug treatment. There was a decrease in the mean (95% CI) viral load from 326 438 (428 600–186 420) copies/mL to 180 495 (258 300–124 000) copies/mL and 22 069 (42 100–16 000) copies/mL after 6 and 12 months of treatment, respectively. The decrease in viral load was associated with an increase in mean (95% CI) CD4 count from a baseline of 243 (203–388) cells/μL to 336 (263–486) cells/μL after 6 months of therapy, and this continued to rise to 527 (285–767) cells/μL (p < 0.001) and 618 (362–1012) cells/μL (p < 0.001) after 12 and 18 months of treatment, respectively. With the exception of mild gastrointestinal adverse effects, the drug was well tolerated. Both patients and investigators rated the treatment as good or very good.

Conclusion: The polyherbal drug Immu-25 showed a favourable effect in patients with HIV infection. The test drug decreased the mean viral load, which was associated with good symptomatic improvement and an increase in the mean CD4 cell count. On the basis of these data, it can be concluded that this herbal drug may have a good immunomodulatory effect and has potential as a co-therapeutic agent in the management of HIV infection. Further studies are warranted to confirm its therapeutic potential.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Table I
Fig. 1
Fig. 2
Table II
Table III

Similar content being viewed by others

References

  1. Weniger BC, Brown T. The march of AIDS through Asia. N Engl J Med 1996; 335: 343–5

    Article  PubMed  CAS  Google Scholar 

  2. Vermani K, Garg S. Herbal medicines for sexually transmitted diseases and AIDS. J Ethnopharmacol 2002 Apr; 80 (1): 49–66

    Article  PubMed  Google Scholar 

  3. Wu JA, Attele AS, Zhang L, et al. Anti-HIV activity of medicinal herbs: usage and potential development. Am J Chin Med 2001; 29 (1): 69–81

    Article  PubMed  CAS  Google Scholar 

  4. Sharma DN, Khosa RL. Immunomodulators of plant origin: a review. Anc Sci Life 1994; 13: 326–9

    Google Scholar 

  5. Bianchi A, Adamoli R, Durante A, et al. The clinical research on medicinal plants used in HIV infection: a bibliographic search. Abstract presented as poster no. 42393 at XII World AIDS Conference at Geneva; 1998

    Google Scholar 

  6. Lu WB, Wen RX, Guan CF. A report on 8 seronegative converted HIV/AIDS patients with traditional Chinese medicine. Zhongguo Zhong Xi Yi Jie He Za Zhi 1997 May; 17 (5): 271–3

    PubMed  CAS  Google Scholar 

  7. Durant J, Gozalez G, Vandermander J, et al. Efficacy and safety of Buxus sempervirens L. preparation (SPV30) in HIV-infected asymptomatic patients: a multicentre, randomised, double-blind, placebo-controlled trial. Phytomedicine 1998; 5: 1–10

    Article  PubMed  CAS  Google Scholar 

  8. Chatterjee S, Das SN. Immunopotentiation by IMMU-21 in immunocompromised rats. Ani Sci Life 1997; 16: 200–5

    CAS  Google Scholar 

  9. Chatterjee S, Das SN. Effect of IMMU-21 on murine peritoneal macrophages and splenic lymphocytes. Ani Sci Life 1996; 15 (4): 250–3

    CAS  Google Scholar 

  10. Pande CB, VijayKumar LA. A study on the immunomodulating action of ZEETRESS. Poult Adv 1994; 27: 53–5

    Google Scholar 

  11. Karnofsky D, Burchenal JH. Clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM, editor. Evaluation of chemotherapeutic agents. New York: Columbia University Press, 1949: 199–205

    Google Scholar 

  12. Thatte UM, Dahanukar SA. Immunotherapeutic modification of experimental infection by Indian medicinal plants. Phytother Res 1989; 3: 43–9

    Article  Google Scholar 

  13. Usha PR, Naidu MUR, Vijay T, et al. Clinical evaluation of efficacy and safety of a new polyherbal drug in the management of HIV infection [abstract]. Published Proceedings of 8th International Congress on Infectious disease 1998; p. 146

    Google Scholar 

  14. Ghosal S, Lal J, Srivastava R, et al. Immunomodulatory and CNS effects of sitoindosides IX and X, two new glycowithanolides from Withania somnifera. Phytother Res 1989; 3: 201–4

    Article  CAS  Google Scholar 

  15. Dahnukar SS, Thatte UM, Rege NN, et al. Immunotherapeutic modification of diverse experimental infections by Tinospora cordifolia, Asparagus and Withania somnifera. Ind J Pharmacol 1989; 21: 53–5

    Google Scholar 

  16. Dahnukar SS, Thatte UM, Rege NN et al. Immunotherapeutic modification of diverse experimental infections by Tinospora cordifolia, asparagus and Withania somnifera. Ind J Pharmacol 1989; 21: 53–5.

    Google Scholar 

Download references

Acknowledgements

The authors thank Indian Herbs Pvt. Ltd. Saharanpur, U.P. India for providing the test drug and research material, and for a research grant for conducting the present study.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to P. R. Usha.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Usha, P.R., Naidu, M.U.R. & Raju, Y.S.N. Evaluation of the Antiretroviral Activity of a New Polyherbal Drug (Immu-25) in Patients with HIV Infection. Drugs R&D 4, 103–109 (2003). https://doi.org/10.2165/00126839-200304020-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200304020-00003

Keywords

Navigation